Clinical trial
TRIUMPH - Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis
NCT07203391 is registered in ClinicalTrials.gov with St Vincent's Hospital, Sydney as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- TRIUMPH - Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis
- Lead sponsor
- St Vincent's Hospital, Sydney
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- February 1, 2026
- Completion date
- December 1, 2029
- Enrollment
- 8 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
uveal melanoma, metastatic